BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 23, 2024
See today's BioWorld
Home
» ODAC Flattens Taltorvic, Cites Risk/Benefit Profile in Sarcoma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ODAC Flattens Taltorvic, Cites Risk/Benefit Profile in Sarcoma
March 21, 2012
By
Catherine Shaffer
No Comments
The FDA's oncologic drugs advisory committee (ODAC) voted 13 to 1 against the approval of Taltorvic (ridaforolimus) by Ariad Pharmaceuticals Inc., partnered with Merck & Co. Inc., for soft-tissue and bone sarcoma.
BioWorld